Meningococcal vaccine groups A C Y W-135 conjugate (second generation) - Sanofi

Drug Profile

Meningococcal vaccine groups A C Y W-135 conjugate (second generation) - Sanofi

Alternative Names: MenACYW conjugate vaccine; Meninge ACTW conj - Sanofi; TetraMen-T

Latest Information Update: 15 Nov 2016

Price : $50

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi
  • Class Meningococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Meningococcal group A infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections

Most Recent Events

  • 03 Nov 2016 Sanofi Pasteur plans a phase III trial for Meningococcal group A, C, Y and W-135 infections in Finland, Germany, hungary and Spain (NCT02955797)
  • 01 Jul 2016 Phase-III clinical trials in Meningococcal group A, C, Y and W-135 infections (In adolescents, In adults, In children, Prevention) in USA (IM) (NCT02842853)
  • 01 Jul 2016 Phase-III clinical trials in Meningococcal group A, C, Y and W-135 infections (In adults, In the elderly, Prevention) in USA (IM) (NCT02842866)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top